BRIUMVI momentum pushes TGTX toward a billion
- BRIUMVI is the whole story today, delivering $228 million of U.S. net product revenue in Q2 2026.
- Management raised 2026 U.S. revenue guidance to a range of $890 million to $905 million after record new patient starts.
- The company expects to exit 2026 at a $1 billion annualized revenue run rate.
- The main risk remains concentration. One drug faces a much larger rival in Roche and Genentech.
- Positive Phase 3 ENHANCE data paves the way for a single starting dose, improving convenience for patients.
A great launch with high expectations
TGTX is a focused biotech with one major product, BRIUMVI. The drug treats relapsing forms of multiple sclerosis, often called RMS. Q2 2026 was exceptionally strong. U.S. BRIUMVI net product revenue hit $228 million, pushing global revenue past $240 million for the quarter.
Management lifted full-year 2026 U.S. revenue guidance again, this time to a range of $890 million to $905 million. The company expects to exit 2026 with a quarterly U.S. net revenue exceeding $250 million. That would secure a $1 billion annualized revenue run rate.
The bull case relies on BRIUMVI expanding its share in the anti-CD20 market for MS. Its one-hour infusion is easy to explain to doctors and patients. New pipeline updates also help. The company reported positive Phase 3 data for a simpler single-day starting dose, and positive early data for a subcutaneous version.
The bear case is simple concentration. This is still a one-product company, and it competes with Roche and Genentech. The Finn view notes that valuation risks remain. After repeated guidance hikes, the stock may need flawless execution to work from here.
One MS drug funds the company
TG Therapeutics makes money by selling BRIUMVI in the United States. The drug is distributed mainly through specialty pharmacies and given in infusion centers. Its key pitch is that it offers an effective anti-CD20 MS therapy with a fast one-hour infusion time.
The company runs as a single business segment. Growth comes from adding new patients, keeping existing patients on the drug, and winning share from older therapies. Cash from BRIUMVI goes toward expanding the commercial effort and funding studies that could improve the drug label.
Earlier in 2026, the company increased its share repurchase authorization to $300 million after securing a new five-year credit facility. This $750 million senior secured credit facility with Blue Owl Capital brought in $500 million of net new capital after repaying old debt.
That capital plan works well while sales climb. However, more debt means the story is less forgiving if BRIUMVI growth slows down or if competitors win back market share.
BRIUMVI and ways to extend it
BRIUMVI IV for relapsing MS
This is the approved product and the core business. It generated $228 million of U.S. net product revenue in Q2 2026.
ENHANCE single-day starting dose
This study tested whether the first two IV starting doses can be combined into one. Top-line Phase 3 data was positive, targeting availability by mid-2027.
Subcutaneous BRIUMVI
This formulation would let patients receive the drug under the skin. After positive Phase 1 bioavailability data, the company expects pivotal Phase 3 data around year-end 2026 or early 2027.
Myasthenia gravis study
TG is exploring BRIUMVI in myasthenia gravis. The company is initiating a registration-directed Phase 2 study.
Treatment-resistant schizophrenia study
This is an early exploratory effort outside the core MS market. It could broaden the company over time, but it is not central to near-term revenue.
Azer-cel
Azer-cel is an off-the-shelf CD19 CAR T-cell therapy being studied in progressive forms of MS and other indications. A clinical update is expected in the second half of 2026.
Mostly U.S. BRIUMVI sales
TG Therapeutics reports one operating segment. For Q2 2026, the company generated $228 million in U.S. BRIUMVI net product revenue out of over $240 million globally, making the U.S. business roughly 95% of the total.
What could break the thesis
BRIUMVI slowdown
High impact · Medium oddsThe company depends heavily on one drug. If new starts slow, if patients stop therapy sooner than expected, or if payers tighten access, the raised 2026 guide could come under pressure. Expectations are now very high.
Roche and Genentech pressure
High impact · High oddsTGTX competes in the anti-CD20 MS market against much larger companies with deep sales reach. BRIUMVI has a clear convenience pitch, but rivals can respond with contracting, doctor outreach, or better delivery options.
Subcutaneous data disappoints
Medium impact · Medium oddsA subcutaneous version could help BRIUMVI compete for patients who prefer at-home dosing. If the pivotal data is weak, that expansion path becomes less valuable. The IV franchise would remain important, but growth would slow.
Debt limits flexibility
Medium impact · Medium oddsThe new $750 million senior secured credit facility gives TG more capital and supports buybacks, but it increases debt. If revenue stalls, interest costs and repayment needs could limit research spending.
Manufacturing or tariff shock
Medium impact · Low oddsBRIUMVI is currently manufactured in South Korea. Management does not expect a material hit from currently proposed tariffs because the cost of goods is low. Still, a supply issue could hurt margins.
In one breath
What does TG Therapeutics sell?
TG Therapeutics sells BRIUMVI, also called ublituximab. It is an anti-CD20 monoclonal antibody used to treat relapsing forms of multiple sclerosis.
Why did TGTX raise its 2026 guidance again?
The company reported $228 million of U.S. BRIUMVI net product revenue in Q2 2026. Management pointed to record new patient enrollments and stronger patient persistence.
What are the biggest upcoming catalysts for TGTX?
The company expects pivotal Phase 3 data for subcutaneous BRIUMVI around year-end 2026 or early 2027. It also expects to launch the simplified ENHANCE single-day starting dose by mid-2027.
Is TG Therapeutics profitable?
The internal view treats the company as solidly profitable after the BRIUMVI launch scaled. The key question is whether profit growth can keep pace with debt, buybacks, and pipeline spending.
